Highly active NK cell and use thereof
US11723924B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 11, 2018 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | Mar 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/2302
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof. (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.